Adoptive cell therapy with young T cells

US8383099B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Mark E. Dudley · Washington, US
• Steven A. Rosenberg · Potomac, US

Key dates

• Filing date: Aug 26, 2010
• Grant date: Feb 26, 2013
• Expiry date: Dec 22, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2501/515
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides a method of promoting regression of a cancer in a mammal comprising (i) culturing autologous T cells; (ii) expanding the cultured T cells; (iii) administering to the mammal nonmyeloablative lymphodepleting chemotherapy; and (iv) after administering nonmyeloablative lymphodepleting chemotherapy, administering to the mammal the expanded T cells, wherein the T cells administered to the mammal are about 19 to about 35 days old and have not been screened for specific tumor reactivity, whereupon the regression of the cancer in the mammal is promoted.